QR code

Propagermanium administration for patients with type 2 diabetes and nephropathy: A randomized pilot trial

Summary Aims We assessed the potential efficacy and safety of propagermanium (PG), an organic compound that inhibits the C–C chemokine receptor type 2, administration in patients with type 2 diabetes and nephropathy. Furthermore, we assessed the feasibility of future studies. Materials and methods W...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Akinori Hara, Miho Shimizu, Erika Hamaguchi, Hirokazu Kakuda, Kenzo Ikeda, Toshiya Okumura, Kiyoki Kitagawa, Yoshitaka Koshino, Motoo Kobayashi, Kazuya Takasawa, Yukimasa Hisada, Tadashi Toyama, Yasunori Iwata, Norihiko Sakai, Takashi Wada
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Wiley 2020-07-01
Reeks:Endocrinology, Diabetes & Metabolism
Onderwerpen:
albuminuria
CCR2
diabetes
kidney
MCP‐1
propagermanium
Online toegang:https://doi.org/10.1002/edm2.159
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items